Monocyte-derived dendritic cells (DCs) from adult T cell leukemia are impaired in taking up exogenous antigens. To overcome this impairment, we fused unpulsed DCs to human T-lymphotropic virus type I (HTLV-I)-infected CD4 ϩ T cells (fusion DC-T cells). The efficiency of fusion was 50% and the fusion cells expressed higher HLA-ABC and CD86 Ags than HTLV-I-infected DCs. The fusion DC-T cells stimulated autologous CD4 ϩ and CD8 ϩ T cells, but DCs fused to itself or PHA-blasts did not stimulate any subsets. The functionally highest fusion DC-T cells was obtained when a DC and HTLV-I-infected T cells were fused at a ratio of 3:1. Expression of HTLV-Igag Ag on CD4 ϩ T cells was up-regulated when infected in the presence of 8-azaguanine, and these fusion DC-T cells were quite efficient in induction of higher CD8
INTRODUCTION
Human T-lymphotropic virus type I (HTLV-I) is an etiological agent of adult T cell leukemia (ATL) and transmission of the virus occurs through breast milk in the newborn period Uchiyama et al., 1977; Hino et al., 1985; Nakano et al., 1986; Kusuhara et al., 1987) . After infection, most individuals do not show monoclonal expansion of HTLV-I-infected CD4 ϩ T cells for more than 40 years (Uchiyama, 1997) . During this asymptomatic carrier state, cytotoxic T lymphocytes of CD8 phenotype seem to work chiefly in inhibiting outgrowth of leukemic T cells (Kannagi et al., 1983 (Kannagi et al., , 1991 Jacobson et al., 1990) . Activation of CD8 ϩ T cells absolutely requires Ag-presenting cells (APCs). Once the immune system has been impaired by unknown mechanisms, HTLV-I-infected individuals are speculated to allow monoclonal expansion of leukemic T cells, which further leads the host into an immunocompromised state (Hollsberg and Hafler, 1993; Funai et al., 1996) . Therefore, ATL manifestation is highly associated with host immunological states. In fact, ATL patients show low T cells responsiveness to Ags in general, and reactivation of uninfected CD4
ϩ T cells and CD8 ϩ T cells is not feasibly induced in vitro (Kannagi et al., 1983 (Kannagi et al., , 1991 . Based on these observations, the most powerful APC should be enrolled in the activation of these T cells. In this respect, dendritic cells (DCs) could be the most potent APCs, because they can stimulate both naive and memory phenotypes of CD4 ϩ and CD8 ϩ T cells (Inaba et al., 1987 (Inaba et al., , 1990 .
In a previous article, we demonstrated that monocytederived DCs were susceptible to HTLV-I infection in vitro and in vivo (Makino et al., 1999) and that the DCs differentiated from peripheral monocytes in ATL patients were impaired in taking up exogenous Ags and stimulating allogeneic T cells (Makino et al., 2000) . Furthermore, peripheral CD4 ϩ T cells in ATL patients could not express CD40 ligand molecules, which play a central role in the differentiation and terminal activation of DCs to mature DCs (Makino et al., 2001) . As far as we know, no efficient or reliable immunotherapeutic tools against ATL have been established, and their urgent development is desired. The most effective tools for immunotherapy against ATL are activated CD8 ϩ T cells, so that the functionally competent DCs should be activated. However, the previous article has indicated that the preparation of functionally competent DCs from peripheral monocytes in ATL patients is difficult (Makino et al., 2001) .
Several immunotherapeutic tools using DCs have recently been developed against malignant tumor cells, including artificial induction of tumor-associated Ags to DCs (Mayordomo et al., 1995; Celluzzi et al., 1996; Hsu et al., 1996; Paglia et al., 1996; Nestle et al., 1998; Nieda et al., 1998) , tumor Ag-specific gene transfection to DCs (Boczkowski et al., 1996; Condon et al., 1996; Gong et al., 1997a; Ribas et al., 1997; Song et al., 1997a,b; Specht et al., 1997) , and fusion of DCs and tumor cells (Gong et al., 1997b (Gong et al., , 1998 (Gong et al., , 2000a Lespagnard et al., 1998; Wang et al., 1998; Kugler et al., 2000) . Among them, the fusion of DCs with tumor cells seems quite useful in vivo as well as in vitro in the induction of MHC class I pathwaymediated CD8 ϩ T cell immunity (Gong et al., 2000a) . Therefore, we examined the effects of fusion of mature DCs from healthy donors and autologous HTLV-I-infected T cells on the APC function for the development of a new immunotherapeutic tool against ATL.
RESULTS

Phenotypic analysis of fusion DC-T cells
Mature DCs, unpulsed with any specific antigen (Ag), were fused with autologous HTLV-I-infected CD4 ϩ T cells and the fusion DC-T cells were analyzed for the expression of surface molecules. Since immature DCs could be infected with cell-free HTLV-I as reported previously (Makino et al., 1999) , DCs infected with the cell-free virions and the mature unpulsed DCs were used as control cells (Fig. 1) . CD2 molecule is a T cell marker and is not expressed on DCs. We used this molecule to monitor the fusion efficiency. Neither DCs unpulsed nor infected with cell-free HTLV-I expressed CD2 Ag; however, around 50% of fusion DC-T cells were CD2 Agpositive when DC population (50-70% of the total population) was analyzed and these CD2-positive cells were considered to be fused. Similar expression of CD3 Ag was observed (not shown). The viability of fusion DC-T cells was around 60-70% among DC population. All of these cells expressed APC-related molecules (MHC, CD86, CD80, CD40, and CD54 Ags); however, the expression levels of MHC class I and CD86 Ags were significantly higher on fusion DC-T cells than on HTLV-I-infected DCs. There were no significant differences among fusion DC-T cells, virus-infected DCs, and unpulsed DCs in the expression of MHC class II, CD80, CD40, and CD54 molecules. Furthermore, fusion DC-T cells faintly expressed HTLV-Igag Ags on the surface (not shown).
Ag-presentation function of fusion DC-T cells
An APC function of Ag-unpulsed mature DCs-autologous HTLV-I-infected CD4 ϩ T cells fusion was examined using autologous mixed lymphocyte reactions (MLRs) (Fig. 2) . All of the mature DCs, HTLV-I-infected CD4 ϩ T cells, and responder T cells were obtained from the same donor. In the process of preparing fusion DC-T cells, there is a possibility of DCs-DCs fusion and HTLV-I-infected T cells-HTLV-I-infected T cells fusion occurring. Therefore, the APC function of fusion DC-T cells was examined in reference to that of DCs-DCs fusion (unpulsed with any Ag) and the T cells-T cells fusion. While these control fusions minimally stimulated autologous T cells, fusion DC-T cells induced significant T cell proliferation. Furthermore, when autologous phytohe- magglutinin-P (PHA) blasts were used as a fusion partner of DCs unpulsed with any Ags, instead of HTLV-Iinfected CD4 ϩ T cells, the DC-PHA blasts fusion did not stimulate autologous T cells. Unfused HTLV-I-infected T cells and the mixture of the T cells and DCs also did not stimulate them (not shown). These results suggest that HTLV-I-infected CD4 ϩ T cells are required as a fusion partner for the induction of vigorous T cell proliferation.
In general, CD4 ϩ T cells are immortalized in vitro by infection with HTLV-I and can be maintained in the presence of interleukin (IL)-2. We determined time-dependent changes of APC function of fusion DC-T cells after fusion (Fig. 3) . The maximum proliferative responses of autologous CD4 ϩ and CD8 ϩ T cells were induced after 24 h of fusion and were rapidly reduced thereafter. The viability of the fusion DC-T cells was also rapidly reduced in a time-dependent manner (not shown) and, at all time points examined, CD4 ϩ T cells were predominantly stimulated. Furthermore, we determined the optimal conditions to obtain fully functional fusion DC-T cells. To this end, we fused DCs with various numbers of HTLV-Iinfected CD4 ϩ T cells (Fig. 4) . The APC function of these cells showed a "bell-shaped phenomenon" and the highest APC function was achieved at a DC:T cell ratio of 3:1. Both fusion DC-T cells prepared under this condition and virus-infected DCs stimulated autologous CD4 ϩ and CD8 ϩ T cells; however, the former induced a significantly higher proliferation of T cells (Fig. 5) .
Relationship between HTLV-I Ag expression on HTLV-I-infected CD4 ϩ T cells and APC function of fusion DC-T cells
It has been reported that metabolic antagonists upregulate the surface expression of tumor-associated Ags (Weber et al., 1994) . We applied this system to HTLV-Iinfection using 8-azaguanine (8Az) as a model compound, because HTLV-I is a causative agent of ATL. CD4 ϩ T cells obtained from healthy donors were infected with HTLV-I in vitro in the presence or absence of 8Az. Seven days after infection, the expression of HTLV-Igag Ag was determined (Fig. 6) . A significantly higher HTLVIgag Ag was expressed on HTLV-I-infected T cells infected in the presence of 8Az than on those prepared in ϩ T cells and CD4
ϩ T cells (T cell/T cell fusion) and mature DCs and autologous PHA blasts (DCs/PHA blasts fusion) were prepared. These fusions were cocultured with autologous unseparated PBMCs (1 ϫ 10 5 /well) for 4 days at a fusion:PBMC ratio of 1:20. A representative of three independent experiments is shown. Each experiment was performed in triplicate and the mean Ϯ standard deviation is shown. the absence of 8Az. We determined the influence of 8Az on the APC function of fusion DC-T cells (Fig. 7) . Although HTLV-I-infected cells produced either with or without 8Az did induce proliferative responses of CD4 ϩ and CD8 ϩ T cells, there was a significant difference in the CD8 ϩ T cells response. A significantly higher proliferation was induced when CD8 ϩ T cells were infected in the presence of 8Az, while no significant difference was observed in the CD4 ϩ T cell response.
DISCUSSION
During an asymptomatic carrier state, CD8 ϩ CTL is thought to play an important role in the suppression of leukemic T cell expansion (Kannagi et al., 1983 (Kannagi et al., , 1991 Jacobson et al., 1990) . For activation of CD8 ϩ T cells, a potent APC is absolutely required. However, DCs obtained from ATL patients were impaired in taking up exogenous Ags in vitro (Makino et al., 2000) . To obtain an immunological tool for overcoming this impairment, an attempt was made to prepare functionally competent DC. 
FIG. 6. Expression of HTLV-Igag Ag on HTLV-I-infected CD4 ϩ T cells. CD4
ϩ T cells were obtained from healthy donors and were infected with HTLV-I using MT-2 cells as a viral source in the presence or absence of 8Az. Seven days after infection, the expression of HTLV-Igag Ag on T cells was determined by using FACScan. PHA blasts were used as a negative control. The number in each panel represents the mean fluorescence intensity. A representative of three independent experiments is shown. Each experiment was performed in triplicate and the mean Ϯ standard deviation is shown.
a P Ͻ 0.05.
FIG. 7. Effect of 8Az treatment on HTLV-I-infected CD4
ϩ T cells. HTLV-I-infected T cells were produced in the absence (Ϫ) or presence (ϩ) of 8Az and were fused with autologous mature DCs. The fusion DC-T cells were cocultured with autologous CD4 ϩ (o) and CD8 ϩ (s) T cells (1 ϫ 10 5 /well) at stimulator:CD4 ϩ T cell ratio of 1:40 and at stimulator:CD8
ϩ T cell ratio of 1:10. A representative of three independent experiments is shown. Each experiment was performed in triplicate and the mean Ϯ standard deviation is shown.
al , 2000a Lespagnard et al., 1998; Wang et al., 1998; Kugler et al., 2000) , and they are found to be especially potent in the induction of MHC class I pathway-mediated polyclonal CD8 ϩ T cell activation, although both MHC class I and II pathways are activated (Wang et al., 1998; Gong et al., 2000a,b) . Furthermore, the fusion cells induce immunity against both known and unidentified multiple antigens and effectively elicits T cell immunity against poorly immunogenic Ags (Gong et al., 1997b; Wang et al., 1998) . Most ATL cells do not express HTLV-I Ags and are considered to be poor immunogenic cancer cells. Therefore, the fusion cells seem to be attractive for the induction of T cell immunity against ATL cells. In our system using HTLV-I-infected CD4 ϩ T cells as a fusion partner of DCs, fusion DC-T cells vigorously stimulated both CD4 ϩ and CD8 ϩ T cell subsets. The extent of stimulation was significantly higher than that induced by HTLV-I-infected DCs. Concerning the CD8 ϩ T cell response, the fusion DC-T cells expressed higher levels of MHC class I and CD86 Ags than HTLV-I-infected DCs (Fig. 1) . These results indicate that fusion DC-T cells might be a potent inducer of higher CD8 ϩ T cells response against HTLV-I Ags. In the case of CD4 ϩ T cell response, there was no significant difference in the expression of MHC class II Ags between fusion DC-T cells and virus-infected DCs. Therefore, the higher CD4 ϩ T cell response might be due to the higher expression of CD86 Ags on fusion DC-T cells.
Concerning the higher proliferative response induction, another explanation might be possible. We have reported previously that, when cell-free HTLV-I virion was used as a viral source, around 10-30% of DCs were infected as far as examined by the surface expression of viral Ags (Makino et al., 2000) . In the present article, the fusion efficiency was as high as 50% when determined by CD2 expression (Fig. 1) . We carefully examined the fusion DC-T cells under microscopy, but did not find any clustered cells. Therefore, higher antigenic load to DC could be achieved by fusion than by in vitro viral infection that might result in the induction of higher proliferative response of CD8 ϩ T cells, although it remains to reveal that the fusion DC-T cells effectively differentiate CD8
ϩ T cells to anti-ATL cytotoxic T cells. The effect of antigenic stimulation to DCs was also observed by the experiment using 8Az, which is a representative metabolic antagonist. The 8Az can up-regulate the expression of intracytoplasmic Ags and is especially useful for Ags with low immunogenicity. In fact, the 8Az was effective in upregulating the expression of HTLV-I Ag on the surface of CD4 ϩ T cells (Fig. 6) . However, 8Az did not largely affect MHC and CD86 Ags expression on fusion DC-T cells (not shown). Therefore, the higher expression of HTLV-I Ag on CD4 ϩ T cells could be associated with a higher CD8 ϩ T cell proliferative response to fusion DC-T cells (Fig. 7) . Taken together, the fusion cells of DCs and HTLV-Iinfected T cells can be considered to be a useful inducer of higher immune response by up-regulating APC-associated and antigenic molecules.
The most important point in evaluating the clinical use of fusion DC-T cells is the fear of inducing autoimmune responses. In this article, this point was assessed by using fusion between DCs and DCs, HTLV-I-infected T cells and HTLV-I-infected T cells, and DCs and autologous PHA-blasts. Neither of these fusions induced a vigorous proliferation of autologous T cells as has been reported by Kugler (Kugler et al., 2000) . Here, we have ruled out the possibility that fusion DC-T cells induce autoimmune responses, although we have to be careful in reaching any definite conclusion, and more detailed analyses including secondary immune responses are required.
Taken together, these results show that mature DCs-HTLV-I-infected CD4 ϩ T cells fusion might be able to provide a potent immunotherapeutic tool against ATL.
MATERIALS AND METHODS
Cell preparation
Peripheral blood mononuclear cells (PBMCs) were obtained from more than 10 uninfected healthy donors and monocyte-derived DCs were differentiated from plastic-adherent monocytes (Makino et al., 1997 (Makino et al., , 1999 . In brief, CD3 ϩ T cells were removed from either freshly isolated or cryopreserved PBMCs using immunomagnetic beads coated with anti-CD3 monoclonal antibody (mAb) (Dynabeads 450, Dynal, Oslo, Norway), and subsequently plastic-adherent monocytes were obtained by washing nonadherent cells extensively. The monocytes were cultured in 10% fetal calf serum for 6 days in the presence of 50 ng of recombinant (r) GM-CSF (Pepro Tech EC Ltd., London, U.K.) and 10 ng of rIL-4 (Pepro Tech EC Ltd.) per milliliter. rGM-CSF and rIL-4 were supplied every 2 days as described previously (Makino et al., 1997 (Makino et al., , 1999 .
Maturation of the DCs was accomplished by treating the immature DCs with 10 ng lipopolysaccharide (LPS, Escherichia coli 0111:B4, Difco Laboratories, Detroit, MI) or 10 ng tumor necrosis factor-␣ (TNF-␣, Boehringer Mannheim GmbH, Germany) per milliliter. The antigenpresenting function of the mature DCs was assessed after treatment with 50 g mitomycin-C per milliliter to block the proliferation of remnant T cells (if any) in the DC population.
Preparation of cell-free HTLV-I virions and infection of T cells with HTLV-I
HTLV-I-producing cell line MT-2, a generous gift from Dr. Y. Tanaka (Ryukyuu Univ. School Medicine, Okinawa, Japan), was used as a viral source. Cell-free HTLV-I virions were prepared by sonicating 5 ϫ 10 6 MT-2 cells per milliliter for 50 s as described before (Makino et al., 2000) . Virions released into the supernatant from the sonicated MT-2 cells were collected and used as a cell-free viral source. As described previously that the cell-free HTLV-I infected to both CD4 ϩ T cells and immature DCs (Makino et al., 1999) , the 50% cell culture infective dose (CCID 50 ) of cell-free HTLV-I was determined using CD4 ϩ T cells as target cells in the presence of 2 g/ml PHA (Difco) and 100 U/ml of rIL-2 (TGP-3, Takeda Chemical Industries, Osaka, Japan). The infection of HTLV-I to CD4 ϩ T cells was determined using PCR. In brief, DNA was extracted from CD4 ϩ T cells using a DNA extractor kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and was amplified by PCR using a primer pair corresponding to nucleotides 1729 to 1750 and 1942 to 1964 of HTLV-Igag region (Makino et al., 1999) . Twenty CCID 50 of HTLV-I virions were infected to the immature DCs. HTLV-I infection was assessed by the measurement of HTLV-Igag Ags on the surface using FACScan (Becton-Dickinson Immunocytometry System, San Jose, CA) as described previously (Makino et al., 1999) .
HTLV-I-infected CD4 ϩ T cells were prepared by infecting HTLV-I to CD4 ϩ T cells donated from healthy donors in vitro. The CD4 ϩ T cells were cocultured with mitomycin-C-treated MT-2 cells in the presence of PHA and rIL-2 and also in the presence or absence of 2.5 g/ml 8Az (Sigma Chemical Co., St. Louis, MO) for 7 days. At day 7 of culture, live-activated T cells were obtained using 30 and 55% gradient Percoll solutions (Pharmacia, Piscataway, NJ) and were maintained in the presence of 2 g/ml PHA and 100 U/ml rIL-2 to establish an HTLV-Iinfected T cell line (Takamoto et al., 1997) .
Preparation of fusion of mature DCs and HTLV-Iinfected CD4 ϩ T cells (fusion DC-T cells)
The monocyte-derived mature DCs were fused with HTLV-I-infected CD4 ϩ T cells in the presence of polyethylene glycol (PEG, MW 4000, Merck, Darmstadt, Germany) as reported by Lespagnard et al. (1998) . In brief, the mature DCs and HTLV-I-infected CD4 ϩ T cells were mixed and washed with prewarmed Dulbecco's PBS (Ϫ) (Nissui Pharmaceutical Co., Tokyo, Japan). These cells were treated with 50% PEG solution for 45 s at room temperature and for another 45 s at 37°C in a water bath. These cells were extensively washed to remove PEG, resuspended in RPMI 1640 medium containing 10% FCS, 50 ng of rGM-CSF, and 10 ng of rIL-4 per milliliter, and cultured for another 24 h at 37°C.
Analysis of cell surface Ags
The expression of cell-surface Ags on the DCs, T cells, and fusion DC-T cells was determined using FACScan. Dead cells were eliminated from the analysis by staining with propidium iodide (Sigma Chemical Co.) and only live cells (1 ϫ 10 4 ) were gated for analysis. We used fluorescein isothiocyanate (FITC)-conjugated mAb against HLA-ABC (G46-2.6) and HLA-DR (L243, Becton-Dickinson), CD40 (5C3, PharMingen, San Diego, CA) and CD80 (BB1, PharMingen), phycoerythrin-labeled mAb against CD54 (HA58; Becton Dickinson) and CD86 (IT2.2, PharMingen), and purified murine mAb to HTLV-I gag Ag (GIN 14) (generously given to us by Dr. Y. Tanaka), which was followed by FITC-labeled Goat F(abЈ) 2 anti-mouse Igs (Tago-Immunologicals, Camarillo, CA), for the analyses of cell-surface antigens. The optimal concentrations of mAbs were determined in advance.
Assessment of antigen-presenting function of HTLV-I-infected DCs and fusion DC-T cells
The APC function of DCs and fusion cells was assessed using mixed autologous DCs and T cells reaction. The virus-infected HTLV-I-infected DCs and fusion DC-T cells were used as a stimulator, and unseparated T cells, purified CD4 ϩ T cells, and CD8 ϩ T cells were used as responder populations. Proliferation of stimulator cells was confirmed to be completely blocked by mitomycin-C. The DCs and fusion DC-T cells were extensively washed and plated to give a stimulator responder ratio of 1:20 or 1:10. The responder T cells were purified as follows: MHC class II ϩ cells were removed from cryopreserved PBMCs using immunomagnetic beads coated with anti-MHC class II mAb (Dynabeads 450, Dynal) and further treated with beads coated with either anti-CD4 mAb or anti-CD8 mAb to select T cell subsets negatively. The purity of CD4 ϩ T cells and CD8 ϩ T cells was more than 98%. Both stimulator and responder cells (1 ϫ 10 5 per well) were plated in 96-well round-bottom tissue culture plates. The cell proliferation during the last 10 h of a 4-day culture in the presence of 4% heatinactivated human serum (a generous gift from Kagoshima Red Cross Blood Center) was quantified by incubating the cells with 1 Ci/well [ 3 H]thymidine. The results are expressed as the mean value in cpm obtained from triplicate cultures.
Statistical analysis
Student's t test was applied to reveal statistically significant differences.
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